Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 132, 108514
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Drug Abuse
This publication has 34 references indexed in Scilit:
- Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrolleesJournal of Substance Abuse Treatment, 2018
- Telemedicine’s Role in Addressing the Opioid EpidemicMayo Clinic Proceedings, 2018
- Methadone in Primary Care — One Small Step for Congress, One Giant Leap for Addiction TreatmentNew England Journal of Medicine, 2018
- Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use DisorderThe Annals of Family Medicine, 2017
- Evaluating barriers to adopting telemedicine worldwide: A systematic reviewJournal of Telemedicine and Telecare, 2016
- Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in GermanyInternational Journal of Drug Policy, 2016
- Medication-Assisted Treatment of Opioid Use DisorderHarvard Review of Psychiatry, 2015
- Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, MarylandAddictive Behaviors, 2013
- Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation ResearchAdministration and Policy in Mental Health and Mental Health Services Research, 2013
- Responses of State Medicaid Programs to Buprenorphine DiversionJAMA Internal Medicine, 2013